We are live on ! Find out more
SABSW icon

SAB Biotherapeutics Warrant
SABSW

13 hedge funds and large institutions have $2.55M invested in SAB Biotherapeutics Warrant in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

34% less capital invested

Capital invested by funds: $3.86M → $2.55M (-$1.31M)

38% less funds holding

Funds holding: 21 → 13 (-8)

60% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 5

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 8

Holders
13
Holders Change
-8
Holders Change %
-38.1%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
5
Closed
8
Calls
$1.1M
Puts
–
Net Calls
+$1.1M
Net Calls Change
-$1.24M

Top Buyers

Rank Fund Capital Flow
1
LP
LMR Partners
United Kingdom
+$271K
2
Morgan Stanley
Morgan Stanley
New York
+$101K

Top Sellers

Rank Fund Capital Flow
1
CH
CVI Holdings
Delaware
-$104K
2
ICMH
Integrity Capital Management (HK)
Hong Kong
-$97K
3
MS
Maven Securities
Jersey
-$90K
4
RCM
Rivernorth Capital Management
Florida
-$84K
5
FBCM
Fort Baker Capital Management
California
-$66K
Name Holding Trade Value Shares
Change 		Change in
Stake
LP
1
LMR Partners
United Kingdom
$1.27M +$271K +320,982 +1,969%
RCM
2
Radcliffe Capital Management
Pennsylvania
$562K -$21.3K -25,205 -31%
SCM
3
Shaolin Capital Management
Florida
$397K -$14.2K -16,796 -2%
Balyasny Asset Management
4
Balyasny Asset Management
Illinois
$129K – – –
Morgan Stanley
5
Morgan Stanley
New York
$72K +$101K +119,439 +380%
YCM
6
Yakira Capital Management
Connecticut
$52K -$6.16K -7,300 -6%
EPM
7
Equitec Proprietary Markets
Illinois
$22K – – –
HF
8
HRT Financial
New York
$20K – – –
Walleye Capital
9
Walleye Capital
New York
$11K – – –
Citadel Advisors
10
Citadel Advisors
Florida
$9K -$119 -141 -0.7%
Walleye Trading
11
Walleye Trading
New York
$7K – – –
Jane Street
12
Jane Street
New York
$5K -$1.88K -2,228 -16%
CH
13
CVI Holdings
Delaware
– -$104K -58,320 Closed
ICMH
14
Integrity Capital Management (HK)
Hong Kong
– -$97K -54,433 Closed
MS
15
Maven Securities
Jersey
– -$90K -50,000 Closed
RCM
16
Rivernorth Capital Management
Florida
– -$84K -46,665 Closed
FBCM
17
Fort Baker Capital Management
California
– -$66K -36,693 Closed
CCM
18
Context Capital Management
California
– -$38K -24,203 Closed
BCM
19
Bluefin Capital Management
New York
– -$34K -19,249 Closed
UBS Group
20
UBS Group
Switzerland
– -$5K -2,888 Closed

SABSW Hedge Fund Activity: Q1 2022 in Review

13 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q1 2022, worth a combined $2.55M — down 34% from $3.86M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of SABSW and 0 opened new positions — a net loss of 8 holders — while 5 trimmed existing stakes and 2 added.

The largest buyer was LMR Partners, adding an estimated $271K. The largest seller was CVI Holdings, exiting entirely with an estimated $104K sold.

  • 13 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q1 2022, down from 21 in Q4 2021.
  • Funds reported $2.55M of SAB Biotherapeutics Warrant stock for Q1 2022, down 34% quarter-over-quarter.
  • 0 funds opened new SAB Biotherapeutics Warrant positions in Q1 2022 and 8 closed out, a net change of -8 holders.
  • The largest SAB Biotherapeutics Warrant buyer in Q1 2022 was LMR Partners, an estimated $271K added.
  • The largest SAB Biotherapeutics Warrant seller in Q1 2022 was CVI Holdings, an estimated $104K sold.

Based on aggregated 13F filings for Q1 2022.